Fibrosuppressant Biotherapeutics
AssigneeUniversity College Dublin, National University of Ireland
InventorsCatherine Godson, Madeline Murphy, Finian Martin, Victoria McEaneney
Life of this patent
Estimating the term…
Abstract
The invention relates to IHG-1 (induced by high glucose-1) a novel gene which encodes a protein that amplifies fibrotic responses in in vitro and in vivo models of fibrotic disorders and in human diabetic nephropathy. In particular the invention relates to modifications of the IHG-1 structure which are potential fibrosuppressant biotherapeutics and modify cellular invasiveness. The invention also relates to a method of screening a therapeutic agent for suitability for the treatment of fibrotic disease comprising testing a candidate therapeutic agent for the ability to reduce the expression of IHG-1 levels in a model system.
Claims15
An IHG-1 protein or a mutant protein thereof for the treatment of fibrotic disease or for the treatment of conditions characterised by dysregulated cellular invasiveness, such as cancers, the protein or mutant having a deleted or inactivated mitochondrial localisation signal.
A protein for the treatment of fibrotic disease or for the treatment of a condition characterised by dysregulated cellular invasiveness, such as cancer, having a sequence selected from the group comprising the sequences shown in FIG. 16.
A pharmaceutical composition comprising a vector is selected from the group comprising plenti6-V5-His, plenti4/TO/V5-DEST, pcDNA6-V5-His and a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.